KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)
September 6, 2024 6:35 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $20.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).
The analyst comments "Bottom Line: We are updating our model following the disclosure of KALV's F1Q financial results and corporate update; the FDA recently accepted sebetralstat's NDA with a PDUFA goal date of June 17, 2025. The company continues to advance lead asset sebetralstat (KVD900), an oral plasma kallikrein inhibitor, towards a commercial launch for the on-demand treatment of... More
